Onconetix vs Exicure
ONCO and XCUR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ONCO and XCUR compare
Onconetix is the larger company, worth 1.8 times as much as Exicure ($12.7M against $7.1M).
Exicure scores higher on the StockData Score (4 against 3 for Onconetix), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ONCO | XCUR |
|---|---|---|
| Size and price | ||
| Market cap | $12.7M | $7.1M |
| Share price | $3.21 | $1.08 |
| Change, 1 year | −99.8% | −70.0% |
| Change, 5 years | −100.0% | −98.4% |
| Beta (5Y) | 4.73 | 1.25 |
| Employees | 12 | 8 |
| StockData Score | ||
| Total score | 3 | 4 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 1 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 19.6× | – |
| P/B | 0.9× (better) | 7.2× |
| Growth | ||
| Revenue growth (TTM) | −51.3% | – |
| Profitability | ||
| Gross margin | 80.4% | – |
| Operating margin | −2525% | – |
| Net margin | −1579% | – |
| Return on equity | −105% (better) | −168% |
| Return on invested capital | −196% (better) | −4377% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −52.4× | – |
| Current ratio | 2.21 (better) | 0.56 |
| Altman Z-score | −12.19 (better) | −27.36 |
| Piotroski F-score | 6 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | – | 0.00% |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 1.7% | 2.1% |
| Held by insiders | 40.3% | 92.6% |
| Insider net buying, 12 months | $8.4K (better) | −$11.6M |
| Short interest, % of float | 40.6% | 10.8% |
Go deeper
- ONCO stock overview
- ONCO income statement
- ONCO valuation and score
- XCUR stock overview
- XCUR income statement
- XCUR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.